Skip to main content Accessibility help
×
Home

Tranexamic acid in ENT

  • Jonathan Fishman, Musheer Hussain and Edward Fisher
  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Tranexamic acid in ENT
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Tranexamic acid in ENT
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Tranexamic acid in ENT
      Available formats
      ×

Abstract

  • An abstract is not available for this content so a preview has been provided below. To view the full text please use the links above to select your preferred format.

Copyright

References

Hide All
1CRASH-3 trial collaborators. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. Lancet 2019;394:1713–23
2Robb, PJ. Tranexamic acid – a useful drug in ENT surgery? J Laryngol Otol 2014;128:574–9
3Williams, A, Biffen, A, Pilkington, N, Arrick, L, Williams, RJ, Smith, ME et al. Haematological factors in the management of adult epistaxis: systematic review. J Laryngol Otol 2017;131:1093–107
4Thakur, A, Gupta, S, Thakur, JS, Minhas, RS, Azad, RK, Vasanthalakshmi, MS et al. Tranexamic acid has no advantage in head and neck surgical procedures: a randomised, double-blind, controlled clinical trial. J Laryngol Otol 2019;133:1024–32
5Chen, CC, Wang, CC, Wang, CP, Lin, TH, Lin, WD, Liu, SA. Prospective, randomized, controlled trial of tranexamic acid in patients who undergo head and neck procedures. Otolaryngol Head Neck Surg 2008;138:762–7
6Das, A, Mitra, S, Ghosh, D, Kumar, S, Sengupta, A. Does tranexamic acid improve intra-operative visualisation in endoscopic ear surgery? A double-blind, randomised, controlled trial. J Laryngol Otol 2019;133:1033–7

Tranexamic acid in ENT

  • Jonathan Fishman, Musheer Hussain and Edward Fisher

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed